AFAP1L2 Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA5117770-Each-of-1 | In Stock | ₹ 39,427.00 |
PIPA5117770 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 39,427.00
GST (18%): ₹ 7,096.86
Total Price: ₹ 46,523.86
Antigen
AFAP1L2
Classification
Polyclonal
Formulation
PBS with 0.03% ProClin 300; pH 7
Gene Accession No.
Q8N4X5
Gene Symbols
AFAP1L2
Immunogen
E. coli-derived Human AFAP1L2 fragment
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human
Form
Liquid
Applications
Immunocytochemistry, Immunoprecipitation, Western Blot
Conjugate
Unconjugated
Gene
AFAP1L2
Gene Alias
actin filament associated protein 1 like 2; actin filament associated protein 1-like 2; actin filament-associated protein 1-like 2; Afap1l2; AFAP1-like protein 2; AU041783; C86904; CTB-1144G6.4; CTB-1144G6.6; KIAA1914; mKIAA1914; phosphatidylinositol 3-kinase-associated protein; RGD1310668; XB130
Host Species
Rabbit
Purification Method
Antigen affinity chromatography, Protein A
Regulatory Status
RUO
Gene ID (Entrez)
84632
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Isotype
IgG
Related Products
Description
- AFAP1L2, also known as XB130, is structurally similar to actin-filament-associated protein (AFAP), containing several SH2- and SH3-binding motifs, two pleckstrin homology domains, a coiled-coil region, and many potential phosphorylation sites
- It interacts with and is phosphorylated by c-Src tyrosine kinase
- Suppression of AFAP1L2 via siRNA reduced Src activity, IL-8 production, EGF-induced phosphorylation of Akt and GSK3beta, and altered cell cycles in human lung epithelial cells suggesting that AFAP1L2 plays a role as an adaptor in the regulation of Src signal transduction and multiple cellular functions
- Recent experiments have shown that AFAP1L2 is highly expressed in thyroid and is the substrate RET/PTC kinase, a thyroid-specific kinase that plays a pathogenic role in papillary thyroid cancer
- Down-regulation of AFAP1L2 in these cancer cells reduced Akt activity, inhibiting cell-cycle progression and cancer cell survival in suspension, indicating that AFAP1L2 may be a valuable target in thyroid cancer therapy
- At least four isoforms of AFAP1L2 are known to exist.